| Title |
How to connect an IgE-driven response with CTL activity?
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, November 2011
|
| DOI | 10.1007/s00262-011-1127-y |
| Pubmed ID | |
| Authors |
Barbara Platzer, Eleonora Dehlink, Shannon J. Turley, Edda Fiebiger |
| Abstract |
One of the goals of cell-based immune therapy in cancer is the induction of tumor-specific cytotoxic T-lymphocyte (CTL) responses. To achieve this objective, the ability of dendritic cells (DC) to cross-present tumor antigens can be exploited. One of the most efficient pathways for the induction of CTLs by cross-presentation is mediated by immunoglobulins of the IgG class, which are used by DCs to sample antigen in the form of immune complexes via Fc-gamma receptors. Could DCs use an IgE-mediated cross-presentation mechanism in a comparable manner to induce CTLs? We here discuss the potential of two human IgE Fc receptors, FcεRI and FcεRII, to serve as antigen uptake receptors for IgE-mediated cross-presentation. We conclude that the existence of an IgE-mediated cross-presentation pathway would provide a direct link between IgE-driven immune responses and CTL activity. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 4% |
| Singapore | 1 | 4% |
| Unknown | 23 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 36% |
| Other | 4 | 16% |
| Student > Ph. D. Student | 4 | 16% |
| Student > Master | 2 | 8% |
| Student > Bachelor | 1 | 4% |
| Other | 4 | 16% |
| Unknown | 1 | 4% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 8 | 32% |
| Immunology and Microbiology | 7 | 28% |
| Medicine and Dentistry | 6 | 24% |
| Biochemistry, Genetics and Molecular Biology | 3 | 12% |
| Unknown | 1 | 4% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 November 2011.
All research outputs
#15,238,442
of 22,656,971 outputs
Outputs from Cancer Immunology, Immunotherapy
#2,151
of 2,882 outputs
Outputs of similar age
#96,406
of 141,726 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#30
of 37 outputs
Altmetric has tracked 22,656,971 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,882 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 141,726 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.